DUBLIN, May 16, 2023 /PRNewswire/ -- Alkermes plc (ALKS) (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry portfolio—which includes LYBALVI ® (olanzapine and ...
̶ Results from Long-Term Safety Study and Data from Healthcare Resource Utilization Research Offer Insights into Treatment Experiences for People Living with Schizophrenia or Bipolar I Disorder ̶ ...
DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced new developments and milestones related to its proprietary product and late-stage pipeline portfolio of medicines for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results